A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for niraparib

Niraparib was approved for the treatment of platinum-sensitive recurrent epithelial ovarian cancer, fallopian tube and primary peritoneal cancer. The authors retrospectively investigated niraparib-related adverse events (AEs) through data mining of the US Food and Drug Administration Adverse Event R...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, Menglin, Shu, Yamin, Chen, Guosong, Li, Juan, Li, Feie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9709073/
https://www.ncbi.nlm.nih.gov/pubmed/36446798
http://dx.doi.org/10.1038/s41598-022-23726-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9709073/
https://www.ncbi.nlm.nih.gov/pubmed/36446798
http://dx.doi.org/10.1038/s41598-022-23726-4

Ejemplares similares